Medifast Inc. (0K05)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 12.55 |
|---|---|
| 52-week range | 9.27 – 13.49 |
| Return, 1 month / 3 months | +3.5% / +28.5% |
| Return, 1 year / 3 years | −2.1% / −82.1% |
| Trend | Uptrend |
| RSI (14) | 61 |
| Volatility (1 year) | 51.8% |
| Worst drawdown (1 year) | -27.4% |
| Average daily value traded | 0.00M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Medifast is a health and wellness company based in the United States that makes and sells weight-management products. Its range includes meal replacements, protein bars, shakes and other foods designed to support weight loss and healthy habits. The company reaches customers largely through a community of independent coaches who guide clients through its programmes, alongside direct sales of its products. Customers are mainly adults looking to manage their weight with structured meal plans and ongoing support.
Medifast Inc. trades under the code 0K05 on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Medifast Inc. (0K05) trades on the London Stock Exchange in UK. It last closed at USD 12.55 on 27 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,914 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 2.1% and over the last three months it rose 28.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 10.6% | ||
| From 52-week high | -5.8% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 28.5% | ||
| 6-month return | 14.6% | ||
| 12-month return, skipping the last month | -5.5% | ||
| Stability (higher is calmer) | 40 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 51.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -27.4% | ||
| Liquidity | 9 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +4.6% |
|---|---|
| 1 month | +3.5% |
| 3 months | +28.5% |
| 6 months | +14.6% |
| 1 year | −2.1% |
| 3 years | −82.1% |
| 5 years | −92.8% |
Signals
| 50-day / 200-day average | 12.01 / 11.35 |
|---|---|
| Golden / death cross (60 days) | Golden, 36 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.57 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Sep 2023 | USD 1.6500 |
| 26 Jun 2023 | USD 1.6500 |
| 27 Mar 2023 | USD 1.6500 |
| 19 Dec 2022 | USD 1.6400 |
| 16 Sep 2022 | USD 1.6400 |
| 27 Jun 2022 | USD 1.6400 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.